Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.
about
Association between the DTNBP1 gene and intelligence: a case-control study in young patients with schizophrenia and related disorders and unaffected siblingsComputational neuropsychiatry - schizophrenia as a cognitive brain network disorderAddressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment optionsThe mGluR2/3 agonist LY379268 blocks the effects of GLT-1 upregulation on prepulse inhibition of the startle reflex in adult rats.GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppressionCircuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaCelecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On TrialsMismatch negativity: translating the potentialThinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signalingInsights into cortical oscillations arising from optogenetic studiesWindows to the soul: vision science as a tool for studying biological mechanisms of information processing deficits in schizophreniaThe neural and genetic basis of executive function: attention, cognitive flexibility, and response inhibition.The role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophreniaRestoration of Sp4 in Forebrain GABAergic Neurons Rescues Hypersensitivity to Ketamine in Sp4 Hypomorphic Mice.Excitation-inhibition discoordination in rodent models of mental disorders.Emotional and cognitive dysregulation in schizophrenia and depression: understanding common and distinct behavioral and neural mechanismsThe impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophreniaNeuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathwayThe post-synaptic density of human postmortem brain tissues: an experimental study paradigm for neuropsychiatric illnessesDysfunctional GABAergic inhibition in the prefrontal cortex leading to "psychotic" hyperactivationAnimal models of neuropsychiatric disordersIncreased hippocampal, thalamic, and prefrontal hemodynamic response to an urban noise stimulus in schizophrenia.GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implicationsModulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.Behavioral effects of the benzodiazepine-positive allosteric modulator SH-053-2'F-S-CH₃ in an immune-mediated neurodevelopmental disruption model.Deletion of PLCB1 gene in schizophrenia-affected patients.The effect of distracting noise on the neuronal mechanisms of attention in schizophrenia.N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinToo little and too much: hypoactivation and disinhibition of medial prefrontal cortex cause attentional deficits.Auditory steady state responses in a schizophrenia rat model probed by excitatory/inhibitory receptor manipulation.Evidence for involvement of nitric oxide and GABA(B) receptors in MK-801- stimulated release of glutamate in rat prefrontal cortexEffect of maternal lipopolysaccharide administration on the development of dopaminergic receptors and transporter in the rat offspring.Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophreniaCysteamine treatment ameliorates alterations in GAD67 expression and spatial memory in heterozygous reeler miceAdolescent onset of cortical disinhibition in schizophrenia: insights from animal models.Increased expression of receptor phosphotyrosine phosphatase-β/ζ is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes.Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.The role of ATP signaling in the migration of intermediate neuronal progenitors to the neocortical subventricular zone.Molecular targets for treating cognitive dysfunction in schizophrenia.
P2860
Q21203814-1B78A36A-F445-4ABE-9661-A2E40DC26D59Q22241226-D16199A4-4238-4C02-9DD0-76ED14FB1783Q22241447-1DDB725F-D335-4CFF-89EA-D5551B5F0CD4Q24603020-B06EB0AC-B578-4499-942A-94C6D967E9A0Q24610466-7EFC8D33-579E-4B3A-B37D-EE5DAA4D3AFDQ24646206-FA6A5E26-F374-4392-8E88-911B37885933Q26741541-25CCB78B-47D7-4CA3-A5BC-0A13D5773348Q26830827-22CAB752-8CF9-4C3F-A2A1-9901DE509010Q26864995-2B403CBC-A7C7-48FF-BA5C-3177298445F9Q26865948-0C6041D5-3E74-4DD6-AAC2-3A5F354C54C4Q26999303-159745B9-721F-4354-BD5F-0DE88C25FEBBQ27013979-A097C344-90B8-4894-999E-8F5954FAA361Q27023087-B25E1F6E-93A1-4592-B73D-9C8E416FD266Q27300750-353FB3D0-6E16-4984-8AC6-37A1AD2586BBQ27692087-18E96EBB-85FD-4E91-A1C2-67DE6FE67CBCQ28073684-CA230AC8-31EB-4CFE-A7DD-F443A754FF35Q28081110-114EF453-7033-4904-82C2-BBA4C9885994Q28285114-C53965C4-F9EA-4B25-892F-1ED47B8AEA56Q28475295-310148EE-80C4-4ADF-B2FD-13B0487E02D4Q28754545-78DFE930-1B0D-4595-899C-82DAC40621CFQ29619899-B402F76F-3984-4579-87A9-61A86F812679Q30374377-D0693C53-9857-4707-B456-F1ECE95D1AE0Q30376372-1FFF4494-0811-4B24-8D37-B6DE2B411835Q30391868-B1B38A89-6741-4CCC-9CCF-5D3D1C29976CQ30405706-B3F58DA3-EA6C-46AA-836C-4E7FD6809A5EQ30415884-475B640C-0E7F-46D8-BA7A-099FED5C5CA7Q30424731-4E363360-CC7C-4F2A-B632-874531FBA6C6Q30427199-47C61F62-E9BB-45F9-87F6-5D91DA25F6DBQ30427775-F1741E74-4265-4398-A85E-5D03ADAA374CQ30436783-2D31DBC6-B37C-4A78-B6E0-90BE837C13C1Q30447745-545754AD-19EC-4D87-AC0C-A9DC3EB534B3Q30450049-CEC50717-73F6-4068-B129-AEB4378A29BEQ30458917-62C4C084-4365-4801-84E2-0039D307D574Q30459624-98ABCBB2-9EC7-478E-ACA6-7F1BEE4D7351Q30464123-DD0C5C89-292C-4CA4-BF65-094EBA019C25Q30468184-B431AC65-49E0-4435-83B6-49A17272514EQ30468818-24FE99BE-B885-4399-9C5A-BFB46503140CQ30473410-E95CC37E-1699-4E36-BFBE-90265B594B93Q30484339-F4C1C4E8-98D1-4A87-A10C-7C8FFB66884FQ30491310-367F3FC6-59B5-4A26-B9E8-8D431ABA5526
P2860
Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Cognitive dysfunction in schiz ...... cid and glutamate alterations.
@ast
Cognitive dysfunction in schiz ...... cid and glutamate alterations.
@en
type
label
Cognitive dysfunction in schiz ...... cid and glutamate alterations.
@ast
Cognitive dysfunction in schiz ...... cid and glutamate alterations.
@en
prefLabel
Cognitive dysfunction in schiz ...... cid and glutamate alterations.
@ast
Cognitive dysfunction in schiz ...... cid and glutamate alterations.
@en
P1433
P1476
Cognitive dysfunction in schiz ...... cid and glutamate alterations.
@en
P304
P356
10.1001/ARCHNEUR.63.10.1372
P577
2006-10-01T00:00:00Z